By clicking "Allow All" you agree to the storing of cookies on your device to enhance site navigation,
analyse site usage and support us in providing free open access scientific content.
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts.
The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types.
Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry for the quantification of thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
Biognosys Announces the Appointment of Kristina Beeler as Chief Business Officer
Biognosys announces strategic agreement with Siemens Healthineers
Boehringer Ingelheim and Biognosys join forces on applying quantitative proteomics tools in drug discovery
Gustave Roussy and Biognosys Announce Partnership
Indivumed and Biognosys partnership aims to enhance proteomics insights
New software will accelerate data-independent acquisition (DIA) proteomics experiments
Biognosys brings proteomic breakthroughs to mainstream users
Proteomics & DIA Mass Spectrometry in Neurodegenerative Disease Research
Advantages of directDIA™ and Spectronaut 15 in Single-Cell Proteomics
Spectronaut: Expand Biological Insights with DIA Proteomics